Naramig (Naratriptan)

Naratriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This action causes vasoconstriction of dilated intracranial arteries and blocks the release of pain‑triggering neuropeptides, interrupting the migraine pain pathway.

The specific dose and dosing schedule for Naramig are determined by the prescribing healthcare professional based on the individual patient's condition, response, and medical history. Patients should follow the prescriber’s instructions and not alter the dose on their own.

The safety of naratriptan in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Naramig, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Naramig (naratriptan) belongs to the triptan class, which is generally more specific for migraine relief than non‑specific analgesics. Compared with other triptans, naratriptan has a longer half‑life, offering sustained relief, but individual response varies and the choice depends on patient tolerance and physician assessment.

Naramig tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Naramig is taken orally, usually as a whole tablet with a glass of water. It should be taken as soon as migraine symptoms begin, and may be repeated after a minimum interval if needed, according to the prescriber’s guidance.

Serious risks include chest pain or tightness, which may indicate cardiac vasospasm, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience these symptoms.

Naramig is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, peripheral vascular disease, or those who have previously experienced an adverse reaction to any triptan. It should also be avoided in patients taking ergotamine derivatives or monoamine oxidase inhibitors.